Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.13 USD
+0.05 (4.63%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.12 -0.01 (-0.88%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 181 - 200 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Selinexor to Take a Bite at the COVID-19 Apple
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
From Underneath The Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive BOSTON Topline Sets Up Expansion into 2L+ Multiple Myeloma
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Phase 3 BOSTON Data for Xpovio in Multiple Myeloma; Raising PT by $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q19 Results; BOSTON Data Expected by End of April; Increasing PT by $3 to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department